Form 4: C4 Therapeutics CSO Reports RSU Vesting & Tax Withholding

Sentiment:

Insider Transaction Report 30 October 2025 4:30 PM

C4 Therapeutics' Chief Scientific Officer, Paige Mahaney, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Summary

Paige Mahaney, Chief Scientific Officer of C4 Therapeutics, Inc. (CCCC), reported transactions on October 28, 2025.
Acquired 19,200 shares of Common Stock upon the vesting of previously granted restricted stock units (RSUs).
Disposed of 5,644 shares of Common Stock at a price of $2.58 per share to satisfy tax withholding obligations related to the RSU vesting.
Following these transactions, Mahaney beneficially owns 99,356 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The filing reports a routine executive compensation event involving the vesting of restricted stock units and subsequent tax-related share withholding, which is a standard practice and does not indicate a significant positive or negative operational or financial development for the company.

Positives

Vesting of 19,200 restricted stock units (RSUs) for Chief Scientific Officer Paige Mahaney, indicating the successful execution of long-term incentive compensation.

Negatives

Disposition of 5,644 shares of Common Stock at $2.58 per share to cover tax withholding obligations, reducing the net shares received by the executive.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders: Dilution from RSU vesting is a known aspect of executive compensation plans, but the number of shares is relatively small in the context of the company's total outstanding shares.
Executive (Paige Mahaney): Receives vested shares, increasing personal stake and aligning interests with shareholders.

Key Dates

Date	Description
10/28/2024	Date of initial RSU grant reported in a previous Form 4.
10/28/2025	Date of transaction (RSU vesting and share disposition).
10/30/2025	Signature date of the filing.

Recommendation

hold

This Form 4 reports a standard executive compensation event (RSU vesting and tax withholding) and does not provide new information that would alter the fundamental investment thesis for C4 Therapeutics. Investors should maintain their current position based on broader company performance and outlook.

Keywords

C4 Therapeutics, CCCC, Form 4, Insider Transaction, RSU Vesting, Executive Compensation, Paige Mahaney, Chief Scientific Officer

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.